Nymox Pharmaceutical Corporation
NYMXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $9,367 | $45,981 | $28,602 | $106,569 |
| - Cash | $74 | $70 | $1,403 | $830 |
| + Debt | $0 | $750 | $173 | $391 |
| Enterprise Value | $9,293 | $46,661 | $27,372 | $106,130 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1 | -$11 | -$12 | -$12 |
| % Margin | – | – | – | – |
| EBITDA | -$4,265 | -$8,772 | -$6,521 | -$12,492 |
| % Margin | – | – | – | – |
| Net Income | -$4,492 | -$8,844 | -$6,576 | -$12,537 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.048 | -0.097 | -0.074 | -0.15 |
| % Growth | 50.3% | -31.1% | 50.9% | – |
| Operating Cash Flow | -$2,601 | -$4,057 | -$5,205 | -$9,820 |
| Capital Expenditures | $0 | -$3 | $0 | -$6 |
| Free Cash Flow | -$2,601 | -$4,060 | -$5,205 | -$9,826 |